Enzyme-Linked Immunosorbent Assay (ELISA) Service

Enzyme-linked immunosorbent assays (ELISA) have been around as one of the primary methods of analyte detection for decades. As the workhorse experiment of any drug development research, high quality and reliable ELISA data is critical for scientific understanding and further investigations.

ACRO's advantage comes from our skilled and experienced staff scientists, large catalog of in-house produced proteins, antibodies including anti-idiotype antibodies as well as our ready-to-use ELISA kits.

We provide a comprehensive ELISA bioassay method development service, including method development, validation, transfer, and kit development, according to each of your needs to help you accelerate your drug development process!

ACROBiosystems provides high-quality absorbance, fluorescence and luminescence measurements by employing SpectraMax i3x system (Molecular Devices). ACROBiosystems has also acquired the ScanLaterTM Western Blot expansion as well as the Alpha Screen 384 STD detection cartridge providing our customers multiple options of analysis.

Benefit

• Sensitivity across spectrum with Spectral Fusion™ Illumination

• Expanded dynamic range with cooled PMT

• Cartridges for FP, AlphaScreen and Western Imaging

Based on the SpectraMax i3x system, ACROBiosystems provides biomedical research and development services for customers seeking quantification and detection of antibodies-antigen interaction. Other services inlcude but are not limited to anti-drug activity (ADA), PK/PD assays as well as antibody screenings.

Analytical report will be delivered in 2 weeks upon sample receipt!

ACROBiosystems provides a comprehensive range of ELISA bioassay method development services starting from assay reagents to sample detection！

One-stop ELISA bioassay method development service

We provide screening services including peptide screening and antibody screening using common methods like competitive ELISA.

For example, we can perform a screening assay for peptide samples using ACROBiosystem's own Anti-SARS-CoV-2 Neutralizing Antibody Titer Serologic Kit (Cat#: RAS-N022).

Fig1. Positive reference for anti-SARS-CoV-2 neutralizing antibody concentrations (μg/mL) for peptide 9 screening (SpectraMax i3x).

Fig2. Sample screening for peptide 9 (uM) using anti-SARS-CoV-2 neutralizing antibody titer serologic Kit (Cat#: RAS-N022) (SpectraMax i3x).

ln addition to antigen affinity screening, affinity of antibody to Fc receptors and C1q is responsible for cell killing via ADCC/ADCP and CDC effects respectively. Therefore testing association of Fc receptors and C1q is necessary during the development phase of antibody drug candidates.

We can perform a binding assay for Human TROP-2 and a client’s antibody to test the efficacy of the provided antibody using our own Human TROP-2 / TACSTD2 Protein, His Tag (Cat#: TR2-H5223). The microplate is coated overnight with TROP-2. The sample antibody is added to the wells, and subsequently the secondary HRP conjugated Goat Anti-Mouse IgG is added. After the primary antibody from the client binds to TROP-2 the HRP secondary antibody will bind to the primary, and following the addition of TMB the intensity of the signal will be proportional to the concentration of primary antibody.

An idiotope is the unique set of antigenic determinants (epitopes) of the variable portion of an antibody. An anti-idiotypic (Anti-ID) antibody binds to the idiotope of another antibody, usually an antibody drug, which makes it a very powerful tool for antibody drug development, especially for immunogenicity and PK/PD analysis.

To support preclinical/clinical immunogenicity and PK analysis, ACROBiosystems has developed a series of high-affinity anti-idiotypic antibodies and ADA/PK services.

ACRO has developed conjugated magnetic beads which can be used in beads based ELISA.